Me ha llegado un correo de una persona de Rankia, solicitándome la dirección para enviarme un obsequio navideño. Supongo que a algunos os habrá llegado también. No sé yo,,,,
Si te sientas en la mesa y no descubres al "primo" es que lo eres tú.
Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma
met its primary endpoint of progression-free survival (PFS).
A significant and clinically meaningful improvement in PFS was demonstrated in IMspire150. The safety profile observed in the trial was consistent with the known safety profiles of the individual medicines.
